GRAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.